Novartis aims to acquire all of Speedel

The Basel pharmaceutical group Novartis plans to fully acquire a research partner – the biotech company Speedel - for about SFr907 million ($882 million).

This content was published on July 10, 2008 - 09:34

Novartis announced on Thursday that in a first step it had raised its stake in Speedel, which has a number of projects targeting heart disease, by 51.7 per cent to 61.4 per cent.

In a statement, Novartis said it had bought the shares from major Speedel shareholders – including 21.5 per cent from Speedel chief executive Alice Huxley – for SFr130 per share in cash.

It said it would offer the same price to shareholders for the remaining stake.

The two companies have worked together to develop a hypertension treatment that became the first new medicine for high blood pressure in more than a decade.

Novartis says the Speedel pipeline provides access to many research and development projects targeting heart disease.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.